Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Heron Therapeutics, Inc. is one of the most promising stocks on our list.

TheFly reported on June 3 that H.C. Wainwright lowered its price target on HRTX to $2 from $4 while maintaining a Buy rating after the U.S. District Court for the District of Delaware ruled against the company in its Cinvanti patent litigation. Although the decision was viewed as a setback for HRTX’s intellectual property protections, the firm noted that the company intends to appeal the ruling to the U.S. Court of Appeals for the Federal Circuit, citing confidence in the strength of its legal arguments and the potential for the decision to be overturned.

The revised price target followed HRTX’s June 2 announcement that the Delaware court had invalidated two patents covering its Cinvanti injectable emulsion in litigation involving Azurity Pharmaceuticals and Slayback Pharma. The company emphasized that the ruling does not affect previously executed settlement agreements related to either Cinvanti or Aponvie injectable emulsion. Heron also reaffirmed its plan to challenge the decision before the Federal Circuit, which has jurisdiction over patent appeals, underscoring its commitment to defending its intellectual property despite the unfavorable district court ruling.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company developing innovative therapies for acute care and oncology using proprietary drug delivery technologies.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Follow Insider Monkey on Google News.